Dutch Crucell's new flu vaccine may outperform Roche's Tamiflu

LONDON An experimental flu vaccine might work better than Roche's Tamiflu, according to preclinical testing data.

The drug, an antibody by Dutch biotech company Crucell designated mAb CR6261, was shown to outperform Tamiflu (oseltamivir phosphate) when tested against several strains of the flu, including the deadly H5N1 avian influenza, though it has yet to enter clinical testing.

Crucell presented data in San Diego at a conference on antibody engineering.